Table 3 Real-life application—primary tumours

From: Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)

Category Subcategory HCC (n = 422) ICC (n = 120) All (n = 542)
Time since primary diagnosis (days) Median 188 201 191
Q1, Q3 71, 590 65, 468 70, 652
Missing 4 (0.9%) 2 (1.7%) 6 (0.1%)
Intention of treatmentc Ablation 17 (4.0%) 7 (5.8%) 24 (4.4%)
Bridge to liver surgery 3 (0.7%) 3 (2.5%) 6 (1.1%)
Bridge to liver transplant 23 (5.5%) 2 (1.7%) 25 (4.6%)
Downsizing / down-staging 137 (32.5%) 25 (20.8%) 162 (29.9%)
Palliative 242 (57.3%) 83 (69.2%) 325 (60.0%)
Prior TARE hepatic procedures Yes 189 (44.8%) 41 (34.2%) 230 (42.4%)
No 233 (55.2%) 79 (65.8%) 312 (57.6%)
Surgical (any)a 72 (17.1%) 32 (26.7%) 104 (19.2%)
Ablation (any) 62 (14.7%) 7 (5.8%) 69 (12.7%)
TACE (any) 97 (23.0%) 2 (1.7%) 99 (18.3%)
Vascular (any) 15 (3.6%) 1 (0.8%) 16 (3.0%)
Abdominal radiotherapy (any) 7 (1.7%) 5 (4.2%) 12 (2.2%)
Prior systemic therapy Yes 45 (10.7%) 73 (60.8%) 118 (21.8%)
No 377 (89.3%) 47 (39.2%) 424 (78.2%)
Concomitant chemotherapyb Yes 32 (7.6%) 11 (9.2%) 43 (7.9%)
No 390 (92.4%) 109 (90.8%) 499 (92.1%)
Post-TARE systemic therapy Yes 125 (29.6%) 45 (37.5%) 170 (31.4%)
No 262 (62.1%) 63 (52.5%) 325 (60.0%)
Missingd 35 (8.3%) 12 (10.0%) 47 (8.7%)
Post-TARE hepatic procedures Yes 80 (19.0%) 20 (16.7%) 100 (18.4%)
No 307 (72.7%) 88 (73.3%) 395 (72.9%)
Missingd 35 (8.3%) 12 (10.0%) 47 (8.7%)
Surgical (any)a 3 (0.7%) 4 (3.3%) 7 (1.3%)
Ablation (any) 11 (2.6%) 4 (3.3%) 5 (2.8%)
TACE (any) 34 (8.1%) 1 (0.8%) 35 (6.5%)
Vascular (any) 7 (1.7%) 2 (1.7%) 9 (1.7%)
Abdominal radiotherapy (any) 13 (3.1%) 6 (5.0%) 19 (3.5%)
  1. aPatients can have multiple prior and post-TARE hepatic procedures
  2. bConcomitant if systemic therapy start date is within 4 weeks of first TARE treatment start date and up to 8 weeks after first TARE end date (where end date is within 42 days of first TARE in case of two sessions)
  3. cIntention of TARE is for first treatment
  4. dMissing data include data from patients that were lost to follow up or deceased before the first follow-up could be included (n = 47)